Latest Conference Articles

A greater portion of patients with metastatic castration-sensitive prostate cancer achieved an early and deep prostate-specific antigen reduction from baseline of 90% or more when treated with apalutamide compared with enzalutamide.

With 9 approved markers in non–small cell lung cancer and a plethora of established and emerging therapies that have been designed to target them, the need for molecular testing is more important than ever.

Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer.

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

Lyudmila Bazhenova, MD, explores key challenges faced with diagnosing and appropriately treating patients with non–small cell lung cancer that harbors EGFR exon 20 insertion mutations and provides insight into the second-line options that have recently garnered regulatory approval.

Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment.

Russell Kenneth Hales, MD, discusses the role of multidisciplinary care in locally advanced lung cancer.

Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer.

Antibody-drug conjugates appear to have the most activity in those with non–small cell lung cancer and HER2 expression.

Repeat histologic evaluation and molecular testing in patients with EGFR-mutant non–small cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions.

Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development.

Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.

In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers.

Upal Basu Roy, PhD, MPH, discusses addressing barriers to biomarker testing in lung cancer.

Russell Kenneth Hales, MD, discusses investigational treatment strategies that have the potential to build upon the positive results of the phase 3 PACIFIC trial in stage III non–small cell lung cancer.

Surgical resection remains the key treatment modality for early-stage non–small cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients.

Alexander Babatunde Olawaiye, MD, discusses factors that influence optimized frontline maintenance therapy in advanced ovarian cancer.

Reviewing some of the most talked about abstracts that were presented at the 2022 Gastrointestinal Cancers Symposium.

Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.

Jubilee Brown, MD, discusses recent developments and upcoming trials exploring minimally invasive surgery in ovarian cancer.

Yovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.

Yovanni Casablanca, MD, discusses the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.

Bradley R. Corr, MD, discusses practice-changing developments and active clinical trials that are being done in endometrial cancer.

The safety and tolerability of TST001 is under investigation as a potential treatment option for patients with gastric/gastroesophageal junction cancer and other locally advanced or metastatic solid tumors as part of a phase 1 trial.

The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.

Trastuzumab deruxtecan demonstrated durable responses and a safety profile that was consistent with findings from the primary analysis of the phase 2 DESTINY-CRC01 trial in pretreated patients with HER2-expressing metastatic colorectal cancer, according to updated results of the study.

The addition of nivolumab to encorafenib and cetuximab elicited a high response rate and an acceptable safety profile in patients with refractory microsatellite stable, BRAF V600E–mutant metastatic colorectal cancer, according to findings from a phase 1/2 trial.

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

The use of pembrolizumab plus binimetinib and bevacizumab in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer induced a median progression-free survival of 5.8 months, according to preliminary findings from a phase 2 trial.